Envoy Medical Inc Dossier
Qualitative Analysis
Business overview
Envoy Medical, Inc. (NASDAQ: COCH) is an early-stage, pre-commercial hearing health company focused on developing and commercializing first-of-its-kind, fully implanted hearing devices. The company's product portfolio addresses the hearing loss spectrum with two primary technologies: the commercially available Esteem active middle ear implant (commercially available in the U.S. since 2010) and the investigational Acclaim fully implanted cochlear implant. Unlike traditional cochlear implants that rely on external microphones and head-worn processors, the Acclaim device utilizes a proprietary piezoelectric sensor to leverage the natural anatomy of the ear to capture sound, leaving the user with no externally worn components.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the clinical development of the investigational Acclaim® fully implanted cochlear implant, focusing on collecting 12-month follow-up data from the 56-patient pivotal trial to support a PMA submission.
Expected impact: Positions Envoy Medical to disrupt the multi-billion-dollar cochlear implant market by offering the first fully implantable solution with no external hardware.
Proactively scaling commercialization planning by training and engaging a network of clinical centers to build sufficient capacity ahead of the anticipated regulatory approval of the Acclaim® device.
Expected impact: Ensures rapid market adoption and surgeon readiness immediately following potential FDA approval.
Expanding the global patent portfolio protecting Envoy Medical's unique fully implanted hearing technologies, including sensor designs that leverage the natural anatomy of the ear instead of external microphones.
Expected impact: Strengthens competitive barriers against established cochlear implant manufacturers and protects next-generation product pipelines.